AT2 receptors: Functional relevance in cardiovascular disease

Pharmacology and Therapeutics

Volumn 120, Issue 3, 2008, Pages 292-316

  Jones, Emma S ^a   Vinh, Antony ^a   McCarthy, Claudia A ^a   Gaspari, Tracey A ^a   Widdop, Robert E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin II; AT1 receptor; AT2 receptor; Cardiovascular disease

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DIABETES MELLITUS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HYPERTENSION; KIDNEY DISEASE; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; AGING; ANIMAL; HUMAN; METABOLISM; PHYSIOLOGY;

AGING; ANGIOTENSINS; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; KIDNEY DISEASES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM;

EID: 56149096807     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.08.009     Document Type: Review

References (446)

1. Abadir P.M., Periasamy A., Carey R.M., and Siragy H.M. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 48 (2006) 316-322
2. AbdAlla S., Lother H., Abdel-tawab A.M., and Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276 (2001) 39721-39726
3. AbdAlla S., Lother H., el Massiery A., and Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 (2001) 1003-1009
4. AbdAlla S., Lother H., and Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 (2000) 94-98
5. Achard V., Boullu-Ciocca S., Desbriere R., Nguyen G., and Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 292 (2007) R274-282
6. Akasu M., Urata H., Kinoshita A., Sasaguri M., Ideishi M., and Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32 (1998) 514-520
7. Akishita M., Horiuchi M., Yamada H., Zhang L., Shirakami G., Tamura K., et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2 (2000) 13-20
8. Akishita M., Ito M., Lehtonen J.Y., Daviet L., Dzau V.J., and Horiuchi M. Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest 103 (1999) 63-71
9. Akishita M., Iwai M., Wu L., Zhang L., Ouchi Y., Dzau V.J., et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102 (2000) 1684-1689
10. Albiston A.L., McDowall S.G., Matsacos D., Sim P., Clune E., Mustafa T., et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276 (2001) 48623-48626
11. Alfakih K., Lawrance R.A., Maqbool A., Walters K., Ball S.G., Balmforth A.J., et al. The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease. Eur Heart J 26 (2005) 584-589
12. Alfakih K., Maqbool A., Sivananthan M., Walters K., Bainbridge G., Ridgway J., et al. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. Hypertension 43 (2004) 1189-1194
13. Allen A.M., Zhuo J., and Mendelsohn F.A. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol 10 (1999) S23-29
14. Ardaillou R., and Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int 52 (1997) 1458-1468
15. Armando I., Jezova M., Juorio A.V., Terron J.A., Falcon-Neri A., Semino-Mora C., et al. Estrogen upregulates renal angiotensin II AT(2) receptors. Am J Physiol Renal Physiol 283 (2002) F934-943
16. Arnold J.M., Yusuf S., Young J., Mathew J., Johnstone D., Avezum A., et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107 (2003) 1284-1290
17. Arun K.H., Kaul C.L., and Poduri R. Tempol augments angiotensin II-induced AT2 receptor-mediated relaxation in diabetic rat thoracic aorta. J Hypertens 22 (2004) 2143-2152
18. Asano K., Dutcher D.L., Port J.D., Minobe W.A., Tremmel K.D., Roden R.L., et al. Selective down-regulation of the angiotensin II AT1-receptor subtype in human ventricular myocardium. Circulation 95 (1997) 1193-1200
19. Baiardi G., Macova M., Armando I., Ando H., Tyurmin D., and Saavedra J.M. Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat. Regulatory Pept 124 (2005) 7-17
20. Baker K.M., and Aceto J.F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 259 (1990) H610-H618
21. Baker K.M., Booz G.W., and Dostal D.E. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54 (1992) 227-241
22. Barber M.N., Sampey D.B., and Widdop R.E. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 34 (1999) 1112-1116
23. Barker T.A., Massett M.P., Korshunov V.A., Mohan A.M., Kennedy A.J., and Berk B.C. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Hypertension 48 (2006) 942-949
24. Bartunek J., Weinberg E.O., Tajima M., Rohrbach S., and Lorell B.H. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation 99 (1999) 22-25
25. Basso N., Paglia N., Stella I., de Cavanagh E.M., Ferder L., del Rosario Lores Arnaiz M., et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regulatory Pept 128 (2005) 247-252
26. Batenburg W.W., de Bruin R.J., van Gool J.M., Muller D.N., Bader M., Nguyen G., et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28 (2008) 1151-1157
27. Batenburg W.W., Garrelds I.M., Bernasconi C.C., Juillerat-Jeanneret L., van Kats J.P., Saxena P.R., et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109 (2004) 2296-2301
28. Batlle M., Roig E., Perez-Villa F., Lario S., Cejudo-Martin P., Garcia-Pras E., et al. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant 25 (2006) 1117-1125
29. Bautista R., Sanchez A., Hernandez J., Oyekan A., and Escalante B. Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure. Hypertension 38 (2001) 669-673
30. Bedecs K., Elbaz N., Sutren M., Masson M., Susini C., Strosberg A.D., et al. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 325 (1997) 449-454
31. Benter I.F., Yousif M.H., Anim J.T., Cojocel C., and Diz D.I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am J Physiol Heart Circ Physiol 290 (2006) H684-691
32. Bockaert J., Marin P., Dumuis A., and Fagni L. The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 546 (2003) 65-72
33. Bonnet F., Candido R., Carey R.M., Casley D., Russo L.M., Osicka T.M., et al. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J Hypertens 20 (2002) 1615-1624
34. Booz G.W. Cardiac angiotensin AT2 receptor: what exactly does it do?. Hypertension 43 (2004) 1162-1163
35. Bottari S.P., King I.N., Reichlin S., Dahlstroem I., Lydon N., and de Gasparo M. The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 183 (1992) 206-211
36. Boulanger C.M., Caputo L., and Levy B.I. Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. Hypertension 26 (1995) 752-757
37. Bouley R., Perodin J., Plante H., Rihakova L., Bernier S.G., Maletinska L., et al. N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. Eur J Pharmacol 343 (1998) 323-331
38. Bove C.M., Gilson W.D., Scott C.D., Epstein F.H., Yang Z., Dimaria J.M., et al. The angiotensin II type 2 receptor and improved adjacent region function post-MI. J Cardiovasc Magn Reson 7 (2005) 459-464
39. Bove C.M., Yang Z., Gilson W.D., Epstein F.H., French B.A., Berr S.S., et al. Nitric oxide mediates benefits of angiotensin II type 2 receptor overexpression during post-infarct remodeling. Hypertension 43 (2004) 680-685
40. Brassard P., Amiri F., and Schiffrin E.L. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 46 (2005) 598-606
41. Brechler V., Reichlin S., De Gasparo M., and Bottari S.P. Angiotensin II stimulates protein tyrosine phosphatase activity through a G-protein independent mechanism. Recept Channels 2 (1994) 89-98
42. Brede M., Hadamek K., Meinel L., Wiesmann F., Peters J., Engelhardt S., et al. Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT(2) receptor. Circulation 104 (2001) 2602-2607
43. Brede M., Roell W., Ritter O., Wiesmann F., Jahns R., Haase A., et al. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension 42 (2003) 1177-1182
44. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
45. Brilla C.G., Zhou G., Matsubara L., and Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26 (1994) 809-820
46. Brilla C.G., Zhou G., Rupp H., Maisch B., and Weber K.T. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 76 (1995) 8D-13D
47. Brillante D.G., Johnstone M.T., and Howes L.G. Effects of intravenous PD 123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin-Angiotensin-Aldosterone Syst 6 (2005) 102-106
48. Brillante, D. G., O'Sullivan, A. J., Johnston, M. T., & Howes, L. G. (2008). Arterial stiffness and haemodynamic response to vasoactive medications in patients with insulin resistant syndrome. Clin Sci 114, 139-147.
49. Brink M., Erne P., de Gasparo M., Rogg H., Schmid A., Stulz P., et al. Localization of the angiotensin II receptor subtypes in the human atrium. J Mol Cell Cardiol 28 (1996) 1789-1799
50. Brown L., Wall D., Marchant C., and Sernia C. Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. J Endocrinol 154 (1997) 355-362
51. Burckle C.A., Jan Danser A.H., Muller D.N., Garrelds I.M., Gasc J.M., Popova E., et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 47 (2006) 552-556
52. Burrell L.M., and Johnston C.I. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs Aging 10 (1997) 421-434
53. Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26 (2005) 369-375 discussion 22-4
54. Busche S., Gallinat S., Bohle R.M., Reinecke A., Seebeck J., Franke F., et al. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 157 (2000) 605-611
55. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
56. Campbell D.J. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol Suppl 3 (1996) S125-131
57. Campbell D.J., Kladis A., and Duncan A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23 (1994) 439-449
58. Campbell D.J., Kladis A., and Valentijn A.J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26 (1995) 233-240
59. Campbell D.J., Lawrence A.C., Towrie A., Kladis A., and Valentijn A.J. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18 (1991) 763-773
60. Cao Z., Bonnet F., Candido R., Nesteroff S.P., Burns W.C., Kawachi H., et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13 (2002) 1773-1787
61. Cao Z., Dean R., Wu L., Casley D., and Cooper M.E. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension 34 (1999) 408-414
62. Cao Z., Kelly D.J., Cox A., Casley D., Forbes J.M., Martinello P., et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58 (2000) 2437-2451
63. Capponi A.M. Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. Blood pressure. Supplement 2 (1996) 41-46
64. Caputo L., Benessiano J., Boulanger C.M., and Levy B.I. Angiotensin II increases cGMP content via endothelial angiotensin II AT1 subtype receptors in the rat carotid artery. Arterioscler Thromb Vasc Biol 15 (1995) 1646-1651
65. Carey R.M., and Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24 (2003) 261-271
66. Carey R.M., Howell N.L., Jin X.H., and Siragy H.M. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 38 (2001) 1272-1277
67. Caron A.Z., Arguin G., and Guillemette G. Angiotensin IV interacts with a juxtamembrane site on AT(4)/IRAP suggesting an allosteric mechanism of enzyme modulation. Regulatory Pept 113 (2003) 9-15
68. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., and Almeida A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 46 (2005) 937-942
69. Chai S.Y., Fernando R., Peck G., Ye S.Y., Mendelsohn F.A.O., Jenkins T.A., et al. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 61 (2004) 2728-2737
70. Chaki S., and Inagami T. New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesis. Mol Pharmacol 43 (1993) 603-608
71. Chapman N., Huxley R., Anderson C., Bousser G., Chalmers J., Colman S., et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. Stroke 35 (2004) 116-121
72. Chen S., Patel J.M., and Block E.R. Angiotensin IV-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release. Am J Physiol Lung Cell Mol Physiol 279 (2000) L849-856
73. Cheng H.F., Burns K.D., and Harris R.C. Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 46 (1994) 1603-1610
74. Chou T.C., Yen M.H., Li C.Y., and Ding Y.A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31 (1998) 643-648
75. Ciuffo G.M., Viswanathan M., Seltzer A.M., Tsutsumi K., and Saavedra J.M. Glomerular angiotensin II receptor subtypes during development of rat kidney. Am J Physiol 265 (1993) F264-271
76. Coleman J.K., Krebs L.T., Hamilton T.A., Ong B., Lawrence K.A., Sardinia M.F., et al. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 19 (1998) 269-277
77. Cosentino F., Savoia C., De Paolis P., Francia P., Russo A., Maffei A., et al. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 18 (2005) 493-499
78. Cote F., Do T.H., Laflamme L., Gallo J.M., and Gallo-Payet N. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 274 (1999) 31686-31692
79. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
80. Csikos T., Gallinat S., and Unger T. Extrarenal aspects of angiotensin II function. Eur J Endocrinol 136 (1997) 349-358
81. Cui T., Nakagami H., Iwai M., Takeda Y., Shiuchi T., Tamura K., et al. ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 279 (2000) 938-941
82. D'Amore A., Black M.J., and Thomas W.G. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46 (2005) 1347-1354
83. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
84. Dai W., Funk A., Herdegen T., Unger T., and Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 20 (1999) 2391-2399
85. Dandapat A., Hu C.P., Chen J., Liu Y., Khan J.A., Remeo F., et al. Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun 366 (2008) 871-877
86. Danser A.H., and Deinum J. Renin, prorenin and the putative (pro)renin receptor. J Renin-Angiotensin-Aldosterone Syst 6 (2005) 163-165
87. Danser A.H., Derkx F.H., Schalekamp M.A., Hense H.W., Riegger G.A., and Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 16 (1998) 853-862
88. Danser A.H., van Kats J.P., Admiraal P.J., Derkx F.H., Lamers J.M., Verdouw P.D., et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 24 (1994) 37-48
89. Daugherty A., and Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14 (2004) 117-120
90. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 (2000) 1605-1612
91. Daugherty A., Manning M.W., and Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134 (2001) 865-870
92. Daugherty A., Rateri D.L., Lu H., Inagami T., and Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110 (2004) 3849-3857
93. Daviet L., Lehtonen J.Y., Tamura K., Griese D.P., Horiuchi M., and Dzau V.J. Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 274 (1999) 17058-17062
94. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
95. de P Rodrigues S.F., dos Santos R.A., Silva-Antonialli M.M., Scavone C., Nigro D., Carvalho M.H.C., et al. Differential effect of losartan in female and male spontaneously hypertensive rats. Life Sci 78 (2006) 2280-2285
96. De Souza A.M., Lopes A.G., Pizzino C.P., Fossari R.N., Miguel N.C.O., Cardozo F.P., et al. Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+-ATPase activity through AT2 receptor. Regulatory Pept 120 (2004) 167-175
97. Diep Q.N., Li J.S., and Schiffrin E.L. In vivo study of AT(1) and AT(2) angiotensin receptors in apoptosis in rat blood vessels. Hypertension 34 (1999) 617-624
98. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., and Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94 (1996) 2756-2767
99. Diez-Freire C., Vazquez J., Correa de Adjounian M.F., Ferrari M.F., Yuan L., Silver X., et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics 27 (2006) 12-19
100. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000) E1-9
101. Dudley D.T., Panek R.L., Major T.C., Lu G.H., Bruns R.F., Klinkefus B.A., et al. Subclasses of angiotensin II binding sites and their functional significance. Mol Pharmacol 38 (1990) 370-377
102. Duke L.M., Eppel G.A., Widdop R.E., and Evans R.G. Disparate roles of AT2 receptors in the renal cortical and medullary circulations of anesthetized rabbits. Hypertension 42 (2003) 200-205
103. Duke L.M., Evans R.G., and Widdop R.E. AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 288 (2005) H2289-2297
104. Duke L.M., Widdop R.E., Kett M.M., and Evans R.G. AT(2) receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. Br J Pharmacol 144 (2005) 486-492
105. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
106. Esteban V., Ruperez M., Sanchez-Lopez E., Rodriguez-Vita J., Lorenzo O., Demaegdt H., et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 96 (2005) 965-973
107. Falcon B.L., Stewart J.M., Bourassa E., Katovich M.J., Walter G., Speth R.C., et al. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension. Physiol Genomics 19 (2004) 255-261
108. Falcon B.L., Veerasingham S.J., Sumners C., and Raizada M.K. Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells. Hypertension 45 (2005) 692-697
109. Faure S., Chapot R., Tallet D., Javellaud J., Achard J.M., and Oudart N. Cerebroprotective effect of angiotensin IV in experimental ischemic stroke in the rat mediated by AT(4) receptors. J Physiol Pharmacol 57 (2006) 329-342
110. Feldman D.L., Jin L., Xuan H., Contrepas A., Zhou Y., Webb R.L., et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52 (2008) 130-136
111. Feldt S., Batenburg W.W., Mazak I., Maschke U., Wellner M., Kvakan H., et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51 (2008) 682-688
112. Feldt S., Maschke U., Dechend R., Luft F.C., and Muller D.N. The putative (pro)renin receptor blocker hrp fails to prevent (pro)renin signaling. J Am Soc Nephrol 19 (2008) 743-748
113. Ferrario C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47 (2006) 515-521
114. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., and Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 30 (1997) 535-541
115. Ferrario C.M., and Iyer S.N. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regulatory Pept 78 (1998) 13-18
116. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005) 2605-2610
117. Ferrario C.M., Trask A.J., and Jessup J.A. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289 (2005) H2281-2290
118. Ferreira A.J., Jacoby B.A., Araujo C.A., Macedo F.A., Silva G.A., Almeida A.P., et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 292 (2007) H1113-1119
119. Fischer T.A., Singh K., O'Hara D.S., Kaye D.M., and Kelly R.A. Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol 275 (1998) H906-916
120. Fukuhara M., Geary R.L., Diz D.I., Gallagher P.E., Wilson J.A., Glazier S.S., et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 35 (2000) 353-359
121. Gallinat S., Busche S., Schutze S., Kronke M., and Unger T. AT2 receptor stimulation induces generation of ceramides in PC12W cells. FEBS Lett 443 (1999) 75-79
122. Georgsson J., Rosenstrom U., Wallinder C., Beaudry H., Plouffe B., Lindeberg G., et al. Short pseudopeptides containing turn scaffolds with high AT2 receptor affinity. Bioorganic Med Chem 14 (2006) 5963-5972
123. Georgsson J., Skold C., Botros M., Lindeberg G., Nyberg F., Karlen A., et al. Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor. J Med Chem 50 (2007) 1711-1715
124. Georgsson J., Skold C., Plouffe B., Lindeberg G., Botros M., Larhed M., et al. Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity. J Med Chem 48 (2005) 6620-6631
125. Gigante B., Piras O., De Paolis P., Porcellini A., Natale A., and Volpe M. Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 16 (1998) 2039-2043
126. Gilbert R.E., Krum H., Wilkinson-Berka J., and Kelly D.J. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet Med 20 (2003) 607-621
127. Gilles R., Vingerhoedt N., Howes J., Griffin M., and Howes L.G. Increase in systemic blood pressure during intra-arterial PD123319 infusion: evidence for functional expression of angiotensin type 2 receptors in normal volunteers. Blood Press 13 (2004) 110-114
128. Gohlke P., Pees C., and Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31 (1998) 349-355
129. Goulter A.B., Goddard M.J., Allen J.C., and Clark K.L. ACE2 gene expression is up-regulated in the human failing heart. BMC Med 2 (2004) 19
130. Grammatopoulos T., Morris K., Ferguson P., and Weyhenmeyer J. Angiotensin protects cortical neurons from hypoxic-induced apoptosis via the angiotensin type 2 receptor. Brain Res Mol Brain Res 99 (2002) 114-124
131. Griendling K.K., Lassegue B., and Alexander R.W. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 36 (1996) 281-306
132. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
133. Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 292 2 (2007) H736-742
134. Grobe J.L., Mecca A.P., Mao H., and Katovich M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 290 (2006) H2417-2423
135. Gross V., Milia A.F., Plehm R., Inagami T., and Luft F.C. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens 18 (2000) 955-961
136. Gross V., Schunck W.H., Honeck H., Milia A.F., Kargel E., Walther T., et al. Inhibition of pressure natriuresis in mice lacking the AT2 receptor. Kidney Int 57 (2000) 191-202
137. Gross V.A., Obst M.A., Kiss E.C., Janke J.B., Mazak I.B., Shagdarsuren E.B., et al. Cardiac hypertrophy and fibrosis in chronic l-NAME-treated AT2 receptor-deficient mice. J Hypertens 22 (2004) 997-1005
138. Groth W., Blume A., Golhlke P., Unger T., and Culman J. Chronic pretreatment with candersartan improves recovery from focal cerebral ischemia in rats. J Hypertens. 21 (2003) 2175-2182
139. Guo D.F., Chenier I., Tardif V., Orlov S.N., and Inagami T. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem Biophys Res Commun 310 (2003) 1254-1265
140. Guo P., Nishiyama A., Rahman M., Nagai Y., Noma T., Namba T., et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade. J Hypertens 24 (2006) 1097-1104
141. Gurley S.B., Allred A., Le T.H., Griffiths R., Mao L., Philip N., et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116 (2006) 2218-2225
142. Guthrie Jr. G.P. Angiotensin receptors: physiology and pharmacology. Clin Cardiol 18 III (1995) 29-34
143. Haithcock D., Jiao H., Cui X.L., Hopfer U., and Douglas J.G. Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol 10 Suppl 11 (1999) S69-S74
144. Hakam A.C., and Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 45 (2005) 270-275
145. Hakam A.C., and Hussain T. Angiotensin II AT2 receptors inhibit proximal tubular Na+-K+-ATPase activity via a NO/cGMP-dependent pathway. Am J Physiol Renal Physiol 290 (2006) F1430-1436
146. Hakam A.C., and Hussain T. Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats. Hypertension 47 (2006) 1117-1124
147. Hakam A.C., Siddiqui A.H., and Hussain T. Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats. Am J Physiol Renal Physiol 290 (2006) F503-508
148. Hamming I., Cooper M.E., Haagmans B.L., Hooper N.M., Korstanje R., Osterhaus A.D.M.E., et al. The emerging role of ACE2 in physiology and disease. J Pathol 212 (2007) 1-11
149. Hannan R.E., Davis E.A., and Widdop R.E. Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol 140 (2003) 987-995
150. Hannan R.E., and Widdop R.E. Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. Curr Hypertens Rep 6 (2004) 117-123
151. Hansen J.L., Servant G., Baranski T.J., Fujita T., Iiri T., and Sheikh S.P. Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. Circ Res 87 (2000) 753-759
152. Hashimoto N., Maeshima Y., Satoh M., Odawara M., Sugiyama H., Kashihara N., et al. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 286 (2004) F516-525
153. Haywood G.A., Gullestad L., Katsuya T., Hutchinson H.G., Pratt R.E., Horiuchi M., et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 95 (1997) 1201-1206
154. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., and Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377 (1995) 744-747
155. Hein L., Meinel L., Pratt R.E., Dzau V.J., and Kobilka B.K. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 11 (1997) 1266-1277
156. Heitsch H., Brovkovych S., Malinski T., and Wiemer G. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 37 (2001) 72-76
157. Henrion D., Kubis N., and Levy B.I. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 38 (2001) 1150-1157
158. Henriques T.A., Huang J., D'Souza S.S., Daugherty A., and Cassis L.A. Orchidectomy, but not ovariectomy, regulates angiotensin II-induced vascular diseases in apolipoprotein E-deficient mice. Endocrinology 145 (2004) 3866-3872
159. Heymes C., Silvestre J.S., Llorens-Cortes C., Chevalier B., Marotte F., Levy B.I., et al. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 139 (1998) 2579-2587
160. Heymes C., Swynghedauw B., and Chevalier B. Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. Circulation 90 (1994) 1328-1333
161. Hill-Kapturczak N., Kapturczak M.H., Block E.R., Patel J.M., Malinski T., Madsen K.M., et al. Angiotensin II-stimulated nitric oxide release from porcine pulmonary endothelium is mediated by angiotensin IV. J Am Soc Nephrol 10 (1999) 481-491
162. Hiyoshi H., Yayama K., Takano M., and Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 45 (2005) 967-973
163. Hiyoshi H., Yayama K., Takano M., and Okamoto H. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension 43 (2004) 1258-1263
164. Horiuchi M., Hayashida W., Kambe T., Yamada T., and Dzau V.J. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 272 (1997) 19022-19026
165. Hu, C., Dandapat, A., Chen, J., Liu, Y., Hermonat, P. L., Carey, R. M., et al. (2008). Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 199, 288-294.
166. Huang Y., Wongamorntham S., Kasting J., McQuillan D., Owens R.T., Yu L., et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69 (2006) 105-113
167. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90 (2005) 783-790
168. Ichihara A., Hayashi M., Kaneshiro Y., Suzuki F., Nakagawa T., Tada Y., et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114 (2004) 1128-1135
169. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M., Suzuki F., Nakagawa T., et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47 (2006) 894-900
170. Ichihara S., Senbonmatsu T., Price Jr. E., Ichiki T., Gaffney F.A., and Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104 (2001) 346-351
171. Ichihara S., Senbonmatsu T., Price Jr. E., Ichiki T., Gaffney F.A., and Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 106 (2002) 2244-2249
172. Ichiki T., Labosky P.A., Shiota C., Okuyama S., Imagawa Y., Fogo A., et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 377 (1995) 748-750
173. Isbell D.C., Voros S., Yang Z., DiMaria J.M., Berr S.S., French B.A., et al. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. Am J Physiol Heart Circ Physiol 293 6 (2007) H3372-H3378
174. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43 (2004) 970-976
175. Ito T., Yamakawa H., Bregonzio C., Terron J., Falcon-Neri A., and Saavedra J. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 33 (2002) 2297-2303
176. Iwai M., Chen R., Li Z., Shiuchi T., Suzuki J., Ide A., et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112 (2005) 1636-1643
177. Iwai M., Liu H., Chen R., I. A., Okamoto S., Hata R., Sakanaka M., et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004)
178. Jacobs L.S., and Douglas J.G. Angiotensin II type 2 receptor subtype mediates phospholipase A2-dependent signaling in rabbit proximal tubular epithelial cells. Hypertension 28 (1996) 663-668
179. Jaiswal N., Tallant E.A., Jaiswal R.K., Diz D.I., and Ferrario C.M. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther 265 (1993) 664-673
180. Jandeleit-Dahm K., Burrell L.M., Johnston C.I., and Koch K.M. Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. J Hypertens 15 (1997) 643-650
181. Jankowski V., Vanholder R., van der Giet M., Henning L., Tolle M., Schonfelder G., et al. Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46 (2005) 591-597
182. Jensen C., Herold P., and Brunner H.R. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7 (2008) 399-410
183. Jin X.Q., Fukuda N., Su J.Z., Lai Y.M., Suzuki R., Tahira Y., et al. Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension 39 (2002) 1021-1027
184. Jin X.H., McGrath H.E., Gildea J.J., Siragy H.M., Felder R.A., and Carey R.M. Renal interstitial guanosine cyclic 3′, 5′-monophosphate mediates pressure-natriuresis via protein kinase G. Hypertension 43 (2004) 1133-1139
185. Jin X.H., Siragy H.M., and Carey R.M. Renal interstitial cGMP mediates natriuresis by direct tubule mechanism. Hypertension 38 (2001) 309-316
186. Johannesson P., Erdelyi M., Lindeberg G., Frandberg P.A., Nyberg F., Karlen A., et al. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem 47 (2004) 6009-6019
187. Johansson M.E., Wickman A., Fitzgerald S.M., Gan L.M., and Bergstrom G. Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE-/- mice. J Hypertens 23 (2005) 1541-1549
188. Johnston C.I. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 10 (1992) S13-S26
189. Jones E.S., Black M.J., and Widdop R.E. Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 37 (2004) 1023-1030
190. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
191. Kalinyak J.E., Sechi L.A., Griffin C.A., Don B.R., Tavangar K., Kraemer F.B., et al. The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 4 (1993) 1337-1345
192. Kang J., Posner P., and Sumners C. Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein. Am J Physiol 267 (1994) C1389-C1397
193. Kaschina E., and Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12 (2003) 70-88
194. Katwa L.C., Campbell S.E., Tyagi S.C., Lee S.J., Cicila G.T., and Weber K.T. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 29 (1997) 1375-1386
195. Keidar S., Gamliel-Lazarovich A., Kaplan M., Pavlotzky E., Hamoud S., Hayek T., et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97 (2005) 946-953
196. Keidar S., Kaplan M., Pavlotzky E., Coleman R., Hayek T., Hamoud S., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 (2004) 2213-2220
197. Kijima K., Matsubara H., Murasawa S., Maruyama K., Mori Y., Ohkubo N., et al. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 79 (1996) 887-897
198. Kim M.P., Zhou M., and Wahl L.M. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 78 (2005) 195-201
199. Kim S., Kawamura M., Wanibuchi H., Ohta K., Hamaguchi A., Omura T., et al. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 92 (1995) 88-95
200. Kintscher U., and Unger T. Does the AT2-receptor mediate anti-atherosclerotic actions?. J Hypertens 23 (2005) 1469-1470
201. Kokje R.J., Wilson W.L., Brown T.E., Karamyan V.T., Wright J.W., and Speth R.C. Central pressor actions of aminopeptidase-resistant angiotensin II analogs: challenging the angiotensin III hypothesis. Hypertension 49 (2007) 1328-1335
202. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F., Heringer-Walther S., Sexton P.M., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
203. Kramar E.A., Harding J.W., and Wright J.W. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regulatory Pept 68 (1997) 131-138
204. Kumar D., Zimpelmann J., Robertson S., and Burns K.D. Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. Nephron Exp Nephrol 96 (2004) e77-88
205. Kurisu S., Ozono R., Oshima T., Kambe M., Ishida T., Sugino H., et al. Cardiac Angiotensin II Type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41 (2003) 99-107
206. Laflamme L., Gasparo M., Gallo J., Payet M., and Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptors in NG108-15 cells. J Biol Chem 271 (1996) 22729-22735
207. Lakatta E.G., and Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 107 (2003) 346-354
208. Lako-Futo Z., Szokodi I., Sarman B., Foldes G., Tokola H., Ilves M., et al. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation 108 (2003) 2414-2422
209. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280 (2005) 30113-30119
210. Lara Lda S., Cavalcante F., Axelband F., De Souza A.M., Lopes A.G., and Caruso-Neves C. Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7). Biochem J 395 (2006) 183-190
211. Lee J., Mustafa T., McDowall S.G., Mendelsohn F.A.O., Brennan M., Lew R.A., et al. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase. J Pharmacol Exp Ther 305 (2003) 205-211
212. Lehtonen J.Y., Horiuchi M., Daviet L., Akishita M., and Dzau V.J. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 274 (1999) 16901-16906
213. Lemos V.S., Silva D.M., Walther T., Alenina N., Bader M., and Santos R.A. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 46 (2005) 274-279
214. Leung P.S., Chan H.C., Fu L.X., and Wong P.Y. Localization of angiotensin II receptor subtypes AT1 and AT2 in the pancreas of rodents. J Endocrinol 153 (1997) 269-274
215. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
216. Lew R.A., Mustafa T., Ye S., McDowall S.G., Chai S.Y., and Albiston A.L. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 86 (2003) 344-350
217. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
218. Li C., Cao L., Zeng Q., Liu X., Zhang Y., Dai T., et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. Cardiovasc Drugs Ther 19 (2005) 105-112
219. Li H., Gao Y., Grobe J.L., Raizada M.K., Katovich M., and Sumners C. Potentiation of the antihypertensive action of losartan by peripheral over expression of the angiotensin II (Ang II) type 2 receptor. Am J Physiol Heart Circ Physiol 292 2 (2006) H727-H735
220. Li J., Culman J., Hortnagl H., Zhao Y., Gerova N., Timm M., et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 10 (2005)
221. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003) 450-454
222. Li X.C., and Widdop R.E. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol 142 (2004) 821-830
223. Lijnen P., Petrov V., Rumilla K., and Fagard R. Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts. Methods Findings Exp Clin Pharmacol 25 (2003) 79-86
224. Lijnen P.J., Petrov V.V., and Fagard R.H. Induction of cardiac fibrosis by angiotensin II. Methods Findings Exp Clin Pharmacol 22 (2000) 709-723
225. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99 (1997) 1926-1935
226. Lokuta A.J., Cooper C., Gaa S.T., Wang H.E., and Rogers T.B. Angiotensin II stimulates the release of phospholipid-derived second messengers through multiple receptor subtypes in heart cells. J Biol Chem 269 (1994) 4832-4838
227. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105 (2002) 1548-1550
228. Lopez-Ilasaca M., Liu X., Tamura K., and Dzau V.J. The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 14 (2003) 5038-5050
229. Lopez J.J., Lorell B.H., Ingelfinger J.R., Weinberg E.O., Schunkert H., Diamant D., et al. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 267 (1994) H844-H852
230. Lorenzo O., Ruiz-Ortega M., Suzuki Y., Ruperez M., Esteban V., Sugaya T., et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 13 (2002) 1162-1171
231. Loufrani L., Henrion D., Chansel D., Ardaillou R., and Levy B.I. Functional evidence for an angiotensin IV receptor in rat resistance arteries. J Pharmacol Exp Ther 291 (1999) 583-588
232. Lu H., Rateri D.L., Feldman Jr. D.L.R.J., Fukamizu A., Ishida J., Oesterling E.G., et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118 (2008) 984-993
233. Lu Q., Zhu Y., and Wong P.T. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 16 (2005) 1963-1967
234. Lucius R., Gallinat S., Busche S., Rosenstiel P., and Unger T. Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 56 (1999) 1008-1019
235. Lucius R., Gallinat S., Rosenstiel P., Herdegen T., Sievers J., and Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 188 (1998) 661-670
236. Ma J., Nishimura H., Fogo A., Kon V., Inagami T., and Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53 (1998) 937-944
237. Masaki H., Kurihara T., Yamaki A., Inomata N., Nozawa Y., Mori Y., et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101 (1998) 527-535
238. Matrougui K., Levy B.I., and Henrion D. Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats. Br J Pharmacol 130 (2000) 521-526
239. Matrougui K., Loufrani L., Heymes C., Levy B.I., and Henrion D. Activation of AT(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension 34 (1999) 659-665
240. Matsubara H., Sugaya T., Murasawa S., Nozawa Y., Mori Y., Masaki H., et al. Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 80 (1998) 25-34
241. Metcalfe B.L., Huentelman M.J., Parilak L.D., Taylor D.G., Katovich M.J., Knot H.J., et al. Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer. Hypertension 43 (2004) 1233-1238
242. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl (2003) S64-S70
243. Mifune M., Sasamura H., Nakazato Y., Yamaji Y., Oshima N., and Saruta T. Examination of angiotensin II type 1 and type 2 receptor expression in human kidneys by immunohistochemistry. Clin Exp Hypertens (NY) 23 (2001) 257-266
244. Mifune M., Sasamura H., Shimizu-Hirota R., Miyazaki H., and Saruta T. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension 36 (2000) 845-850
245. Min L.J., Cui T.X., Yahata Y., Yamasaki K., Shiuchi T., Liu H.W., et al. Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes. Endocrinology 145 (2004) 253-260
246. Miura S., and Karnik S.S. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 19 (2000) 4026-4035
247. Miura S., Karnik S.S., and Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem 280 (2005) 18237-18244
248. Miyata N., Park F., Li X.F., and Cowley Jr. A.W. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol 277 (1999) F437-F446
249. Moeller I., Clune E.F., Fennessy P.A., Bingley J.A., Albiston A.L., Mendelsohn F.A., et al. Up regulation of AT4 receptor levels in carotid arteries following balloon injury. Regulatory Pept 83 (1999) 25-30
250. Mogi M., Iwai M., and Horiuchi M. Emerging concepts of regulation of angiotensin II receptors. new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 27 12 (2007) 2532-2539
251. Mogi M., Jian-Mei L., Iwanami J., Min L., Tsukuda K., Iwai M., et al. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 48 (2006) 141-148
252. Morrissey J.J., and Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 276 (1999) F39-F45
253. Morsing P. Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 10 Suppl 11 (1999) S248-S254
254. Mukoyama M., Horiuchi M., Nakajima M., Pratt R.E., and Dzau V.J. Characterization of a rat type 2 angiotensin II receptor stably expressed in 293 cells. Mol Cell Endocrinol 112 (1995) 61-68
255. Muller D.N., Fischli W., Clozel J.P., Hilgers K.F., Bohlender J., Menard J., et al. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 82 (1998) 13-20
256. Muller D.N., Klanke B., Feldt S., Cordasic N., Hartner A., Schmieder R.E., et al. (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 51 (2008) 676-681
257. Munzenmaier D.H., and Greene A.S. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension 27 (1996) 760-765
258. Muthalif M.M., Benter I.F., Uddin M.R., Harper J.L., and Malik K.U. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther 284 (1998) 388-398
259. Nahmias C., Cazaubon S.M., Briend-Sutren M.M., Lazard D., Villageois P., and Strosberg A.D. Angiotensin II AT2 receptors are functionally coupled to protein tyrosine dephosphorylation in N1E-115 neuroblastoma cells. Biochem J 306 (1995) 87-92
260. Nakajima M., Hutchinson H.G., Fujinaga M., Hayashida W., Morishita R., Zhang L., et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci 92 (1995) 10663-10667
261. Nguyen G. Renin/prorenin receptors. Kidney Int 69 (2006) 1503-1506
262. Nguyen G., Delarue F., Burckle C., Bouzhir L., Giller T., and Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109 (2002) 1417-1427
263. Nickenig G., and Bohm M. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. Eur J Med Res 2 (1997) 285-289
264. Nio Y., Matsubara H., Murasawa S., Kanasaki M., and Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95 (1995) 46-54
265. Nishimura H., Yerkes E., Hohenfellner K., Miyazaki Y., Ma J., Hunley T.E., et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 3 (1999) 1-10
266. Nishimura Y., Ito T., and Saavedra J. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31 (2000) 2478-2486
267. Nora E.H., Munzenmaier D.H., Hansen-Smith F.M., Lombard J.H., and Greene A.S. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol 275 (1998) H1395-H1403
268. Nouet S., Amzallag N., Li J.M., Louis S., Seitz I., Cui T.X., et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 279 (2004) 28989-28997
269. Nussberger J., Aubert J.F., Bouzourene K., Pellegrin M., Hayoz D., and Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 51 (2008) 1306-1311
270. Ohkubo N., Matsubara H., Nozawa Y., Mori Y., Murasawa S., Kijima K., et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96 (1997) 3954-3962
271. Oishi Y., Ozono R., Yano Y., Teranishi Y., Akishita M., Horiuchi M., et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41 (2003) 814-818
272. Okumura M., Iwai M., Ide A., Mogi M., Ito M., and Horiuchi M. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension 46 (2005) 577-583
273. Oro C., Qian H., and Thomas W.G. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 113 (2007) 210-226
274. Ozono R., Wang Z.Q., Moore A.F., Inagami T., Siragy H.M., and Carey R.M. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 30 (1997) 1238-1246
275. Padia S.H., Howell N.L., Siragy H.M., and Carey R.M. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 47 (2006) 537-544
276. Padia S.H., Kemp B.A., Howell N.L., Fournie-Zaluski M.C., Roques B.P., and Carey R.M. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Hypertension 51 (2008) 460-465
277. Padia S.H., Kemp B.A., Howell N.L., Siragy H.M., Fournie-Zaluski M.C., Roques B.P., et al. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 49 (2007) 625-630
278. Parker S.B., Wade S.S., and Prewitt R.L. Pressure mediates angiotensin II-induced arterial hypertrophy and PDGF-A expression. Hypertension 32 (1998) 452-458
279. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
280. Patel J.M., Martens J.R., Li Y.D., Gelband C.H., Raizada M.K., and Block E.R. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol 275 (1998) L1061-L1068
281. Paul M., Poyan Mehr A., and Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 86 (2006) 747-803
282. Phoon S., and Howes L.G. Role of angiotensin type 2 receptors in human forearm vascular responses of normal volunteers. Clin Exp Pharmacol Physiol 28 (2001) 734-736
283. Phoon S., and Howes L.G. Forearm vasodilator response to angiotensin II in elderly women receiving candesartan: role of AT(2)-receptors. J Renin-Angiotensin-Aldosterone Syst 3 (2002) 36-39
284. Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend R., Gratze P., et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.[see comment]. Hypertension 46 (2005) 569-576
285. Pinaud F., Bocquet A., Dumont O., Retailleau K., Baufreton C., Andriantsitohaina R., et al. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension 50 (2007) 96-102
286. Pinheiro S.V., Simoes e Silva A.C., Sampaio W.O., de Paula R.D., Mendes E.P., Bontempo E.D., et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44 (2004) 490-496
287. Pueyo M.E., Arnal J.F., Rami J., and Michel J.B. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol 274 (1998) C214-C220
288. Pupilli C., Lasagni L., Romagnani P., Bellini F., Mannelli M., Misciglia N., et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 10 (1999) 245-255
289. Rajapakse N.W., Eppel G.A., Widdop R.E., and Evans R.G. ANG II type 2 receptors and neural control of intrarenal blood flow. Am J Physiol Regul Integr Comp Physiol 291 (2006) R1669-R1676
290. Rajapakse N.W., Sampson A.K., Eppel G.A., and Evans R.G. Angiotensin II and nitric oxide in neural control of intrarenal blood flow. Am J Physiol Regul Integr Comp Physiol 289 (2005) R745-R754
291. Reaux A., Fournie-Zaluski M.C., and Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metabol 12 (2001) 157-162
292. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5 (2006) 425-438
293. Regitz-Zagrosek V., Friedel N., Heymann A., Bauer P., Neuss M., Rolfs A., et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 91 (1995) 1461-1471
294. Reinecke K., Lucius R., Reinecke A., Rickert U., Herdengen T., and Unger T. Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kB. FASEB J 17 (2003) 2094-2096
295. Reudelhuber T.L. The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 46 (2005) 1261-1262
296. Reudelhuber T.L. A place in our hearts for the lowly angiotensin 1-7 peptide?. Hypertension 47 (2006) 811-815
297. Rice G.I., Thomas D.A., Grant P.J., Turner A.J., and Hooper N.M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383 (2004) 45-51
298. Rihal C.S., Nishimura R.A., Hatle L.K., Bailey K.R., and Tajik A.J. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 90 (1994) 2772-2779
299. Rizkalla B., Forbes J.M., Cao Z., Boner G., and Cooper M.E. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens 23 (2005) 153-164
300. Rizkalla B., Forbes J.M., Cooper M.E., and Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 14 (2003) 3061-3071
301. Rogg H., de Gasparo M., Graedel E., Stulz P., Burkart F., Eberhard M., et al. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 17 (1996) 1112-1120
302. Rosenstrom U., Skold C., Lindeberg G., Botros M., Nyberg F., Hallberg A., et al. Synthesis and AT2 receptor-binding properties of angiotensin II analogues. J Pept Res 64 (2004) 194-201
303. Rosenstrom U., Skold C., Plouffe B., Beaudry H., Lindeberg G., Botros M., et al. New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists. J Med Chem 48 (2005) 4009-4024
304. Roulston C.L., Lawrence A.J., Jarrott B., and Widdop R.E. Localization of AT(2) receptors in the nucleus of the solitary tract of spontaneously hypertensive and Wistar Kyoto rats using [125I] CGP42112: upregulation of a non-angiotensin II binding site following unilateral nodose ganglionectomy. Brain Res 968 (2003) 139-155
305. Rowe B.P., Saylor D.L., Speth R.C., and Absher D.R. Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regulatory Pept 56 (1995) 139-146
306. Ruiz-Ortega M., Esteban V., Suzuki Y., Ruperez M., Mezzano S., Ardiles L., et al. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl (2003) S21-S26
307. Saavedra J.M., Benicky J., and Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol 26 (2006) 1099-1111
308. Saito S., Hirata Y., Emori T., Imai T., and Marumo F. Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertens Res Clin Exp 19 (1996) 201-206
309. Sales V.L., Sukhova G.K., Lopez-Ilasaca M.A., Libby P., Dzau V.J., and Pratt R.E. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 112 (2005) 3328-3336
310. Salomone L.J., Howell N.L., McGrath H.E., Kemp B.A., Keller S.R., Gildea J.J., et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension 49 (2007) 155-161
311. Sampson, A. K., Moritz, K. M., Jones, E. S., Flower, R. L., Widdop, R. E., & Denton, K. M. (2008). Enhanced AT2R-vasodilator mechanisms mediate Ang II-induced decreases in arterial pressure in female rats. Hypertension 52, 666-671.
312. Santos R.A.S., and Ferreira A.J. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 16 (2007) 122-128
313. Santos R.A., Campagnole-Santos M.J., and Andrade S.P. Angiotensin-(1-7): an update. Regulatory Pept 91 (2000) 45-62
314. Santos R.A., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47 (2006) 996-1002
315. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100 (2003) 8258-8263
316. Sardinia M.F., Hanesworth J.M., Krishnan F., and Harding J.W. AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 15 (1994) 1399-1406
317. Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., and Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 163 (2003) 879-887
318. Savoia C., Ebrahimian T., He Y., Gratton J.P., Schiffrin E.L., and Touyz R.M. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens 24 (2006) 2417-2422
319. Savoia C., Tabet F., Yao G., Schiffrin E.L., and Touyz R.M. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 23 (2005) 1037-1045
320. Savoia C., Touyz R.M., Volpe M., and Schiffrin E.L. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (2006)
321. Savoia C., Touyz R.M., Volpe M., and Schiffrin E.L. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49 (2007) 341-346
322. Schefe J.H., Menk M., Reinemund J., Effertz K., Hobbs R.M., Pandolfi P.P., et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 99 (2006) 1355-1366
323. Scheuer D.A., and Perrone M.H. Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 264 (1993) R917-R923
324. Schmieder R.E., Erdmann J., Delles C., Jacobi J., Fleck E., Hilgers K., et al. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 37 (2001) 175-182
325. Schrader J., Luders S., Kulschewski A., Berger J., Zidek W., Treib J., et al. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 (2003) 1699-1703
326. Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36 (2005) 1218-1226
327. Sechi L.A., Griffin C.A., and Schambelan M. The cardiac renin-angiotensin system in STZ-induced diabetes. Diabetes 43 (1994) 1180-1184
328. Senbonmatsu T., Ichihara S., Price Jr. E., Gaffney F.A., and Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106 (2000) R25-R29
329. Senbonmatsu T., Saito T., Landon E.J., Watanabe O., Price Jr. E., Roberts R.L., et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J 22 (2003) 6471-6482
330. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98 (1998) 2282-2289
331. Seyedi N., Xu X., Nasjletti A., and Hintze T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26 (1995) 164-170
332. Shanmugam S., Llorens-Cortes C., Clauser E., Corvol P., and Gasc J.M. Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. Am J Physiol 268 (1995) F922-F930
333. Shenoy U.V., Richards E.M., Huang X.C., and Sumners C. Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain. Endocrinology 140 (1999) 500-509
334. Shibasaki Y., Mori Y., Tsutumi Y., Masaki H., Sakamoto K., Murasawa S., et al. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 51 (1999) 83-91
335. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole -7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole -7-carboxylate (TCV-116). J Pharmacol Exp Ther 266 (1993) 114-120
336. Shiota N., Miyazaki M., and Okunishi H. Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 20 (1992) 168-174
337. Silva-Antonialli M.M., Fortes Z.B., Carvalho M.H., Scivoletto R., and Nigro D. Sexual dimorphism in the response of thoracic aorta from SHRs to losartan. Gen Pharmacol 34 (2000) 329-335
338. Silva-Antonialli M.M., Tostes R.C., Fernandes L., Fior-Chadi D.R., Akamine E.H., Carvalho M.H., et al. A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res 62 (2004) 587-593
339. Simon G., Illyes G., and Csiky B. Structural vascular changes in hypertension: role of angiotensin II, dietary sodium supplementation, blood pressure, and time. Hypertension 32 (1998) 654-660
340. Siragy H.M., and Carey R.M. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 97 (1996) 1978-1982
341. Siragy H.M., and Carey R.M. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100 (1997) 264-269
342. Siragy H.M., and Carey R.M. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33 (1999) 1237-1242
343. Siragy H.M., de Gasparo M., and Carey R.M. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 35 (2000) 1074-1077
344. Siragy H.M., de Gasparo M., El-Kersh M., and Carey R.M. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38 (2001) 183-186
345. Siragy H.M., Inagami T., and Carey R.M. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol 293 (2007) R1461-R1467
346. Siragy H.M., Inagami T., Ichiki T., and Carey R.M. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 96 (1999) 6506-6510
347. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier K., Galle J., et al. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 131 (2000) 667-672
348. Steckelings U.M., Kaschina E., and Unger T. The AT2 receptor-a matter of love and hate. Peptides 26 (2005) 1401-1409
349. Stoll M., Steckelings U.M., Paul M., Bottari S.P., Metzger R., and Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95 (1995) 651-657
350. Strauss M.H., and Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114 (2006) 838-854
351. Strawn W.B., Ferrario C.M., and Tallant E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33 (1999) 207-211
352. Stroth U., Meffert S., Gallinat S., and Unger T. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res Mol Brain Res 53 (1998) 187-195
353. Su J.Z., Fukuda N., Jin X.Q., Lai Y.M., Suzuki R., Tahira Y., et al. Effect of AT2 receptor on expression of AT1 and TGF-beta receptors in VSMCs from SHR. Hypertension 40 (2002) 853-858
354. Sugawara T.H.K., Oda M., Shoji H., Omae T., and Mizoi K. Candesartan reduces superoxide production after global cerebral ischemia. Neuropharmacol Neurotox 16 (2005) 325-328
355. Sugino H., Ozono R., Kurisu S., Matsuura H., Ishida M., Oshima T., et al. Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension 37 (2001) 1394-1398
356. Suzuki J., Iwai M., Nakagami H., Wu L., Chen R., Sugaya T., et al. Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106 (2002) 847-853
357. Suzuki J., Matsubara H., Urakami M., and Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 73 (1993) 439-447
358. Swanson G.N., Hanesworth J.M., Sardinia M.F., Coleman J.K., Wright J.W., Hall K.L., Miller-Wing A.V., Stobb J.W., Cook V.I., Harding E.C., et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regulatory Pept 40 (1992) 409-419
359. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79 (1999) 215-262
360. Tamarat R., Silvestre J.S., Durie M., and Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Investig 82 (2002) 747-756
361. Tea B.S., Der Sarkissian S., Touyz R.M., Hamet P., and deBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 35 (2000) 1069-1073
362. Tejera N., Gomez-Garre D., Lazaro A., Gallego-Delgado J., Alonso C., Blanco J., et al. Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol 164 (2004) 1817-1826
363. Thomas W.G. Regulation of angiotensin II type 1 (AT1) receptor function. Regulatory Pept 79 (1999) 9-23
364. Thone-Reineke C., Steckelings U.M., and Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 24 (2006) S115-S121
365. Thorup C., Kornfeld M., Goligorsky M.S., and Moore L.C. AT1 receptor inhibition blunts angiotensin II-stimulated nitric oxide release in renal arteries. J Am Soc Nephrol 10 Suppl 11 (1999) S220-S224
366. Thorup C., Kornfeld M., Winaver J.M., Goligorsky M.S., and Moore L.C. Angiotensin-II stimulates nitric oxide release in isolated perfused renal resistance arteries. Pflugers Arch Eur J Physiol 435 (1998) 432-434
367. Timmermans P.B., Wong P.C., Chiu A.T., and Herblin W.F. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 12 (1991) 55-62
368. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45 (1993) 205-251
369. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000) 33238-33243
370. Touyz R.M., and Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 35 (2002) 1001-1015
371. Touyz R.M., Endemann D., He G., Li J.S., and Schiffrin E.L. Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. Hypertension 33 (1999) 366-372
372. Touyz R.M., He G., El Mabrouk M., and Schiffrin E.L. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 37 (2001) 574-580
373. Touyz R.M., Tabet F., and Schiffrin E.L. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30 (2003) 860-866
374. Tsurumi Y., Tamura K., Tanaka Y., Koide Y., Sakai M., Yabana M., et al. Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney Int 69 (2006) 488-494
375. Tsutsumi Y., Matsubara H., Masaki H., Kurihara H., Murasawa S., Takai S., et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104 (1999) 925-935
376. Tsutsumi Y., Matsubara H., Ohkubo N., Mori Y., Nozawa Y., Murasawa S., et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 83 (1998) 1035-1046
377. Tsuyuki R.T., and McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 114 (2006) 855-860
378. Tsuzuki S., Matoba T., Eguchi S., and Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 28 (1996) 916-918
379. Unger T., Chung O., Csikos T., Culman J., Gallinat S., Gohlke P., et al. Angiotensin receptors. J Hypertens Supplement 14 (1996) S95-S103
380. Varagic J., Susic D., and Frohlich E.D. Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors. Hypertension. 37 (2001) 1399-1403
381. Vazquez E., Coronel I., Bautista R., Romo E., Villalon C.M., Avila-Casado M.C., et al. Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation. Am J Physiol Renal Physiol 288 (2005) F207-F213
382. Verma S., and Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 329 (2004) 1248-1249
383. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277 (2002) 14838-14843
384. Vincent J.M., Kwan Y.W., Chan S.L., Perrin-Sarrado C., Atkinson J., and Chillon J.M. Constrictor and dilator effects of angiotensin II on cerebral arterioles. Stroke 36 (2005) 2691-2695
385. Vinh, A., Widdop, R. E., Drummond, G. R., & Gaspari, T. A. (2008a). Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 77, 178-187.
386. Vinh, A., Widdop, R. E., Chai, S. Y., & Gaspari, T. A. (2008b). Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. Atherosclerosis 200, 37-44.
387. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
388. Viswanathan M., and Saavedra J.M. Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides 13 (1992) 783-786
389. Viswanathan M., Stromberg C., Seltzer A., and Saavedra J.M. Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta. J Clin Invest 90 (1992) 1707-1712
390. Von Bohlen und Halbach O., Walther T., Bader M., and Albrecht. Genetic deletion of angiotensin AT2 receptor leads to increased cell numbers in different brain structures of mice. Regulatory Pept 99 (2001) 209-216
391. Vongpatanasin W., Thomas G.D., Schwartz R., Cassis L.A., Osborne-Lawrence S., Hahner L., et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115 (2007) 1020-1028
392. Voros S., Yang Z., Bove C.M., Gilson W.D., Epstein F.H., French B.A., et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. Am J Physiol Heart Circ Physiol 290 (2006) H1004-H1010
393. Walters P.E., Gaspari T.A., and Widdop R.E. Angiotensin III acts as a vasodepressor agent via AT2R. Hypertension 42 (2003) 443
394. Walters P.E., Gaspari T.A., and Widdop R.E. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45 (2005) 960-966
395. Walther T., Olah L., Harms C., Maul B., Bader M., Hortanagl H., et al. Ischemic injury in experimental stroke depends on angiotensin II. Stroke. 16 (2002) 169-176
396. Wan Y., Wallinder C., Johansson B., Holm M., Mahalingam A.K., Wu X., et al. First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo. J Med Chem 47 (2004) 1536-1546
397. Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A.K., Wu X., et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47 (2004) 5995-6008
398. Wang H., Gallinat S., Li H.W., Sumners C., Raizada M.K., and Katovich M.J. Elevated blood pressure in normotensive rats produced by 'knockdown' of the angiotensin type 2 receptor. Exp Physiol 89 (2004) 313-322
399. Wang M., Takagi G., Asai K., Resuello R.G., Natividad F.F., Vatner D.E., et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41 (2003) 1308-1316
400. Wang Z.Q., Millatt L.J., Heiderstadt N.T., Siragy H.M., Johns R.A., and Carey R.M. Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Hypertension 33 (1999) 96-101
401. Warnecke C., Kaup D., Marienfeld U., Poller W., Yankah C., Grafe M., et al. Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases. J Mol Med 79 (2001) 510-521
402. Warnecke C., Mugrauer P., Surder D., Erdmann J., Schubert C., and Regitz-Zagrosek V. Intronic ANG II type 2 receptor gene polymorphism 1675 G/A modulates receptor protein expression but not mRNA splicing. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1729-R1735
403. Warner F.J., Lew R.A., Smith A.I., Lambert D.W., Hooper N.M., and Turner A.J. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 280 (2005) 39353-39362
404. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
405. Wassmann S., Czech T., van Eickels M., Fleming I., Bohm M., and Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110 (2004) 3062-3067
406. Weber K.T. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96 (1997) 4065-4082
407. Weber K.T., Sun Y., and Katwa L.C. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 29 (1997) 31-42
408. Wehbi G.J., Zimpelmann J., Carey R.M., Levine D.Z., and Burns K.D. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 280 (2001) F254-F265
409. Whaley-Connell A., Habibi J., Cooper S.A., DeMarco V.G., Hayden M.R., Stump C.S., et al. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 295 (2008) E103-E109
410. Wharton J., Morgan K., Rutherford R.A., Catravas J.D., Chester A., Whitehead B.F., et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 284 (1998) 323-336
411. Wheeler-Schilling T.H., Kohler K., Sautter M., and Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci 11 (1999) 3387-3394
412. Whitebread S., Mele M., Kamber B., and de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163 (1989) 284-291
413. Widdop R.E., Jones E.S., Hannan R.E., and Gaspari T.A. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br J Pharmacol 140 (2003) 809-824
414. Widdop R.E., Matrougui K., Levy B.I., and Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 40 (2002) 516-520
415. Widdop R.E., Vinh A., Henrion D., and Jones E.S. Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol 35 (2008) 386-390
416. Wiemer G., Dobrucki L.W., Louka F.R., Malinski T., and Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 40 (2002) 847-852
417. Wilkinson-Berka J.L. Diabetes and retinal vascular disorders: role of the reninangiotensin system. Exp Rev Mol Med 6 (2004) 1-18
418. Wright J.W., Krebs L.T., Stobb J.W., and Harding J.W. The angiotensin IV system: functional implications. Front Neuroendocrinol 16 (1995) 23-52
419. Wright J.W., Miller-Wing A.V., Shaffer M.J., Higginson C., Wright D.E., Hanesworth J.M., et al. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull 32 (1993) 497-502
420. Wright J.W., Stubley L., Pederson E.S., Kramar E.A., Hanesworth J.M., and Harding J.W. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19 (1999) 3952-3961
421. Wright J.W., Tamura-Myers E., Wilson W.L., Roques B.P., Llorens-Cortes C., Speth R.C., et al. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol Regul Integr Comp Physiol 284 (2003) R725-R733
422. Wruck C.J., Funke-Kaiser H., Pufe T., Kusserow H., Menk M., Schefe J.H., et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 25 (2005) 57-64
423. Wu L., Iwai M., Nakagami H., Chen R., Suzuki J., Akishita M., et al. Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice. Arterioscler Thromb Vasc Biol 22 (2002) 49-54
424. Wu L., Iwai M., Nakagami H., Li Z., Chen R., Suzuki J., et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 (2001) 2716-2721
425. Wysocki J., Ye M., Soler M.J., Gurley S.B., Xiao H.D., Bernstein K.E., et al. ACE and ACE2 activity in diabetic mice. Diabetes 55 (2006) 2132-2139
426. Xu J., Carretero O.A., Liu Y.H., Shesely E.G., Yang F., Kapke A., et al. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40 (2002) 244-250
427. Yamada H., Akishita M., Ito M., Tamura K., Daviet L., Lehtonen J.Y., et al. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 33 (1999) 1414-1419
428. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47 (2006) 718-726
429. Yan X., Price R.L., Nakayama M., Ito K., Schuldt A.J.T., Manning W.J., et al. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 285 (2003) H2179-H2187
430. Yang Z., Bove C.M., French B.A., Epstein F.H., Berr S.S., DiMaria J.M., et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 106 (2002) 106-111
431. Yayama K., Hiyoshi H., Imazu D., and Okamoto H. Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension 48 (2006) 958-964
432. Yayama K., Horii M., Hiyoshi H., Takano M., Okamoto H., Kagota S., et al. Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload. J Pharmacol Exp Ther 308 (2004) 736-743
433. You D., Loufrani L., Baron C., Levy B.I., Widdop R.E., and Henrion D. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 111 (2005) 1006-1011
434. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
435. Zhang X., Lassila M., Cooper M.E., and Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 43 (2004) 276-281
436. Zhao Y., Biermann T., Luther C., Unger T., Culman J., and Gohlke P. Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem 85 (2003) 759-767
437. Zhou J., Pavel J., Macova M., Yu Z.X., Imboden H., Ge L., et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 37 (2006) 1271-1276
438. Zhu M., Gelband C.H., Moore J.M., Posner P., and Sumners C. Angiotensin II type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid. J Neurosci 18 (1998) 679-686
439. Zhu Y.C., Zhu Y.Z., Lu N., Wang M.-J., Wang Y.-X., and Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol 30 (2003) 911-918
440. Zhu Y.Z., Chimon G.N., Zhu Y.C., Lu Q., Li B., Hu H.Z., et al. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 11 (2000) 1191-1194
441. Zhuo J., Dean R., MacGregor D., Alcorn D., and Mendelsohn F.A. Presence of angiotensin II AT2 receptor binding sites in the adventitia of human kidney vasculature. Clin Exp Pharmacol Physiol Suppl 3 (1996) S147-S154
442. Zhuo J., Ohishi M., and Mendelsohn F.A. Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Hypertension 33 (1999) 347-353
443. Zimmerman B.G., and Dunham E.W. Tissue renin-angiotensin system: a site of drug action?. Annu Rev Pharmacol Toxicol 37 (1997) 53-69
444. Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R., et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 108 (2003) 1707-1712
445. Zulli A., Burrell L.M., Widdop R.E., Black M.J., Buxton B.F., and Hare D.L. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J Histochem Cytochem 54 (2006) 147-150
446. Zwart A.S., Davis E.A., and Widdop R.E. Modulation of AT1 receptor-mediated contraction of rat uterine artery by AT2 receptors. Br J Pharmacol 125 (1998) 1429-1436